[eYsYs]

If we talk about the broader perspective, so much credit should go to the Indian Supreme court and its patent office for taking bold stance, time and again, on this broken patent system, allowing generics to make affordable ones.

For example: http://en.wikipedia.org/wiki/Novartis_v._Union_of_India_%26_... talks about how cancer drug were made affordable. Novartis (Switzerland) set the price of Gleevec at USD 2666 per patient per month (which is almost double of India's annual per-capita nominal GDP USD1414); Whereas, generic companies were selling their versions at USD 177 to 266 per patient per month. We can safely presume the situation to be much worse in Africa.

Based on this possibility, support is being replicated to Africa, notably for cancer, AIDS and TB.